Follow-up after primary therapy of malignant epithelial ovarian tumors

Bratislava Medical Journal

Volumn 112, Issue 10, 2011, Pages 579-585

  Lajtman, E ^a   Mlyncek, M ^a   Uharcek, P ^a   Matejka, M ^a  

^a The Philosopher University in Nitra Geoinformatics and Regional Development   (Slovakia)

Author keywords

Malignant epithelial ovarian tumors; Primary therapy; Screening; Treatment

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

BLOOD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; METASTASIS; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; REVIEW; SECOND LOOK SURGERY; TUMOR RECURRENCE;

CA-125 ANTIGEN; FEMALE; GYNECOLOGICAL EXAMINATION; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SECOND-LOOK SURGERY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 81855177028     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. http://data.nczisk.sk/rocenky/rocenka_2007.pdf
2. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005; 97: 519-523.
3. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005; 17: 399-411.
4. Menon U, Skates SJ, Lewis S et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005; 23: 7919-7926.
5. Pecorelli S. 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynec Obstet 2006; 95 (Suppl 1): S161-S163.
6. Zanetta G, Chiari S, Rota S et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997; 104: 1030-1035.
7. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Can cer Inst 2003; 95: 105-112.
8. Young R, Walton LA, Ellenberg SS et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Result of two prospective randomized trials. N Engl J Med 1990; 322: 1021-1027.
9. Vergote IB, Vergote-De Vos LN, Abeler VM et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69:741-749.
10. Rubin SC, Wong GY, Curtin JP et al. Platinum-based chemotherapy of high-risk stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993; 82: 143-147.
11. Petru E, Lahousen M, Tamussino K et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994; 170: 656-662.
12. Malmstrom H, Simonsen E, Westberg R. A phase II study of in-traperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 1994; 52: 20-25.
13. Bolis G, Colombo N, Pecorelli S et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 1995; 6: 887-893.
14. Gadducci A, Sartori E, Maggino T et al. Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study. Int J Gynecol Cancer 1997; 7: 445-450.
15. Nagele F, Petru E, Medl M et al. Preoperative CA 125: An independent prognostic factor in patients with stage I epithelial ovarian can cer. Obstet Gynecol 1995; 86: 259-264.
16. Piver MS, Malfetano J, Baker TR et al. Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol 1992; 46: 357-360.
17. O'Brien ME, Schofield JB, Tan S et al. Clear cell epithelial ova rian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250-254.
18. Vergote I, Trimbos BJ. Treatment of patients with early epithelial ovarian cancer. Curr Opin Oncol 2003; 15: 452-455
19. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
20. Conte PF, Cianci C, Gadducci A. Up date in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol 1999; 32: 49-58.
21. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
22. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-3092.
23. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-115.
24. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
25. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1309-1329.
26. Mano MS, Awada A, Minisini A et al. Remaining controversies in the upfront management of advanced ovarian cancer. Int J Gynecol Can cer 2004; 14: 707-720.
27. Gadducci A, Sartori E, Maggino T et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 1998; 68: 150-155.
28. Ovarian cancer: screening, treatment, and follow-up. NIH Consens Statement 1994; 12: 1-30.
29. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol 2003; 30: 401-412.
30. von Georgi R, Schubert K, Grant P, Munstedt K. Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Re-prod Biol 2004; 114: 228-233.
31. Nicklin JL, Copeland LJ, Luesley D et al. Second-look surgery. In: Gershenson DM, McGuire WP, eds. Ovarian cancer: Controversies in management. New York: Churcill Livingstone, 1998: 85-100.
32. Creasman WT. Second-look laparotomy in ovarian cancer. Gynecol Oncol 1994; 55: S122-S127.
33. Copeland LJ, Vaccarello L, Lewandowski GS. Second-look la parotomy in epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994; 21: 155-166.
34. Podratz KC, Schray MF, Wieand HS et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988; 31: 9-24.
35. Hainsworth JD, Grosh WW, Burnett LS et al. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165-170.
36. Chambers SK, Chambers JT, Kohorn El et al. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988; 72: 404-408.
37. Luesley D, Lawton F, Blackledge G et al. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 2: 599-603.
38. Hoskins WJ, Rubin SC, Dulaney E et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989; 34: 365-371.
39. Maggioni A, Colombo N, Parma G et al. The role of secondary cytoreduction (SC) at the time of second look surgery in advanced ova rian carcinoma: long-term follow-up [abstract]. Int J Gynecol Cancer 1997; 7 (Suppl 2): 079a.
40. Gadducci A, Iacconi P, Fanucchi A et al. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian can cer. Anticancer Res 2000; 20: 1959-1964.
41. Obermair A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand 2001; 80: 432-436.
42. Dowdy SC, Constantinou CL, Hartmann LC et al. Long-term follow-up of women with ovarian cancer after positive second-look la parotomy. Gynecol Oncol 2003; 91: 563-568.
43. Rahaman J, Dottino P, Jennings TS et al. The second-look opera tion improves survival in suboptimally debulked stage III ovarian can cer patients. Int J Gynecol Cancer 2005; 15: 19-25.
44. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cyto reduction for advanced ovarian carcinoma. N Engl J Med 2004; 351: 2489-2497.
45. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1-12.
46. Fioretti P, Gadducci A, Ferdeghini M et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol 1992; 44: 155-160.
47. Rustin GJS, Nelstrop AE, Tuxen MK et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996; 7: 361-364.
48. Santillan A, Garg R, Zahurak ML et al. Risk of epithelial ova rian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23:9338-9343.
49. Gadducci A, Cosio S, Zola P et al. Surveillance procedures for patiens treated for epithelial ovarian cancor: a review of the literature. Int J Gynecol Cancer 2007; 17: 21-31.
50. Gadducci A, Cosio S, Zanca G et al. Evolving role of serum bio-markers in the management of ovarian cancer. Women Health 2006; 2: 141-158.
51. Diamandis EP, Yousef GM, Soosaipillai AR et al. Human kal-likrein 6 (zyme/protease M/neurosin): a new serum biomarker of ova rian carcinoma. Clin Biochem 2000; 33: 579-583.
52. Diamandis EP, Scorilas A, Fracchioli S et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003; 21: 1035-1043.
53. Luo LY, Katsaros D, Scorilas A et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003; 63: 807-811.
54. Diamandis EP, Okui A, Mitsui S et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002; 62: 295-300.
55. Gadducci A, Sartori E, Zola P et al. Serum CA125 assay in the early diagnosis of recurrent epithelial ovarian cancer: a CTF study. On col Rep 1996; 3: 301-303.
56. Sutphen R, Xu Y, Wilbanks GD et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 1185-1191.
57. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005; 97: 15-319.
58. Meier W, Baumgartner L, Stieber P et al. CA125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res 1997; 17: 3019-3020.
59. Sharma A, Bernacki RJ. Ovarian cancer patients with high CA-125 but no symptoms-should antiangiogenic treatments be considered? Oncol Res 1997; 9: 53-54.
60. Gadducci A, Conte P, Cianci C et al. Treatment options in pa tients with recurrent ovarian cancer. Anticancer Res 2001; 21: 3557-3564.
61. Fleming LW. Playing the waiting game... the asymptomatic patient with recurrent ovarian cancer detected only by rising Cal25 le vels. Scott Med J 2001; 46: 81-83.
62. http://www.cancer.gov/clinicaltrials/results/early-chemo-ovarian0609
63. http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vm-view=vm_se ssion presentations_view&confID=65&sessionID=351
64. Fehm T, Heller F, Kramer S et al. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anti cancer Res 2005; 25: 1551-1554.
65. Zanetta G, Rota S, Lissoni A et al. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol On col 2001; 81: 63-66.
66. Caserta D, Marci R, Porzio G et al. Pelvic relapses in ovarian cancer. Role of CA-125, transvaginal ultrasound and color Doppler.Eur J Gynaecol Oncol. 2003; 24: 269-270.
67. Clarke-Pearson DL, Bandy LC, Dudzinski M et al. Computed tomography in evaluation of patients with ovarian carcinoma in com plete clinical remission. Correlation with surgical-pathologic findings. JAMA 1986; 255: 627-630.
68. Silverman PM, Osborne M, Dunnick NR et al. CT prior to se cond-look operation in ovarian cancer. AJR Am J Roentgenol 1988; 150:829-832.
69. Reuter KL, Griffin T, Hunter RE. Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients. Cancer 1989; 63: 1123-1128.
70. De Rosa V, Mangoni di Stefano ML, Brunetti A et al. Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan. Eur J Gynaecol Oncol 1995; 16: 123-129.
71. Topuz E, Aydiner A, Saip P et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic fin dings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol 2000; 21: 599-602.
72. Cho SM, Ha HK, Byun JY et al. Usefulness of FDG-PET for as sessment of early recurrent epithelial ovarian cancer. AJR Am J Roent genol 2002; 179:391-395.
73. Picchio M, Sironi S, Messa C et al. Advanced ovarian carcinoma: usefulness of [(18)F]-FDG-PET in combination with CT for lesion de tection after primary treatment. Q J Nucl Med 2003; 47: 77-84.
74. Funt SA, Hricak H, Abu-Rustum N et al. Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 2004; 182: 393-398.
75. Kerr VE, Cadman E. Pulmonary metastases in ovarian cancer. Cancer 1985; 56: 1209-1213.
76. Dauplat J, Hacker NF, Nieberg RK et al. Distant metastases in epithelial ovarian carcinoma. Cancer 1987; 60:1561-1566.
77. Sella T, Rosenbaum E, Edelmann DZ et al. Value of chest CT scans in routine ovarian carcinoma follow-up. AJR Am J Roentgenol 2001; 177: 857-859.
78. Forstner R, Hricak H, Powel CB et al. Ovarian cancer recurrence: value of MR imaging. Radiology 1995; 196: 715-720.
79. Low RN, Carter WD, Saleh F et al. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT. Radiology 1995; 195: 391-400.
80. Semelka RC, Lawrence PH, Shoenut JP et al. Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre- and postcontrast, fat-suppressed MR imaging, with histologic correlation. J Magn Reson Imaging 1993; 3: 99-106.
81. Outwater EK, Siegelman ES, Wilson KM et al. Benign and ma lignant gynecologic disease: clinical importance of fluid and peritoneal enhancement in the pelvis at MR imaging. Radiology 1996; 200: 483-488.
82. Low RN, Barone RM, Lacey C et al. Peritoneal tumor: MR ima ging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997; 204: 513-520.
83. Kubik-Huch RA, Dorffler W, von Schulthess GK et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10: 761-767.
84. Kainz C, Prayer L, Gitsch G et al. The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries. J Am Coll Surg 1994; 178: 239-244.
85. Buist MR, Golding RP, Burger CW et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994; 52: 191-198.
86. Rose PG, Faulhaber P, Miraldi F et al. Positive emission tomography for evaluating a complete clinical response in patients with ova rian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001; 82: 17-21.
87. Nakamoto Y, Saga T, Ishimori T et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001; 176: 1449-1454.
88. Berger KL, Nicholson SA, Dehdashti F et al. FDG-PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopatho-logic features. AJR Am J Roentgenol 2000; 174: 1005-1008.
89. Bristow RE, Simpkins F, Pannu HK et al. Positron emission tomography for detecting clinically occult surgically resectable metasta-tic ovarian cancer. Gynecol Oncol 2002; 85: 196-200.
90. Drieskens O, Stroobants S, Gysen M et al. Positron emission tomography with FDG in the detection of peritoneal and retroperito-neal metastases of ovarian cancer. Gynecol Obstet Invest 2003; 55: 130-134.
91. Zimny M, Siggelkow W, Schroder W et al. 2-[Fluorine-18]-fluo-ro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001; 83: 310-315.
92. Menzel C, Dobert N, Hamscho N et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strah-lenther Onkol 2004; 180: 497-501.
93. Pannu HK, Cohade C, Bristow RE et al. FDG-PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging 2004; 29: 398-403.
94. Nanni C, Rubello D, Farsad M et al. 18F-FDG FDG-PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005; 31: 792-797.
95. Bristow RE, del Carmen MG, Pannu HK et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined FDG-PET/CT. Gynecol Oncol 2003; 90: 519-528.
96. Gadducci A, Cosio S, Conte PF et al. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 2005; 55: 153-166.
97. http://www.mdanderson.org/diseases/Ovarian/.
98. Robova H, Rob L, Svoboda B et al. Guidelines gynekologickych zhoubnych nadoru I. Standard - Komplexni lecba ovarialnich epitelial-nich zhoubnych nadoru. Ces Gynek 2006; 71: 237-246.
99. Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol 1997; 8: 1081-1087.
100. Wattchow DA, Weller DP, Esterman A et al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 2006; 94: 1116-1121.
101. Grunfeld E, Levine MN, Julian JA, Coyle D, Szechtman B, Mirsky D, Verma S, Dent S, Sawka C, Pritchard KI et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 2006; 24: 848-855.
102. Khatcheressian JL, Smith TJ. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 2006; 24: 835-837.
103. Grunfeld E, Levine MN, Julian JA et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 2006; 24: 848-855.
104. http://www.cancer.gov/clinicaltrials/results/family-doctors0106.
105. Adlard JW, Joseph J, Brammer CV, Gerrard GE. Open access follow-up for lung cancer: patient and start satisfaction. Clin Oncol (R Coll Radiol) 2001; 13: 404-408.